AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VITAPORT
Description: Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ergoselect II 100/200
Description: Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ergoselect II 100/200
Description: Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SpiroScout
Description: Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpiroScout
Description: Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mobil-O-Graph® PWA
Description: Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobil-O-Graph® PWA
Description: Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
Study NCT02509559 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saliva collection
Description: Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
Study NCT02509559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saliva collection
Description: Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
Study NCT01969266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: PCI-32765
Description: 840 mg capsule formulation administered by mouth on Day 1
Study NCT01969266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: PCI-32765
Description: 840 mg solution formulation administered by mouth on Day 1
Study NCT01767584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 1g tablets
Description: Reference product
Study NCT01875952 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isoniazid
Description: Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
Study NCT01767584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 1g tablets
Description: Test product
Study NCT03228368 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab (MPDL3280A)
Description: anti-programmed death-ligand 1 (PD-L1) antibody
Study NCT00640094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
Study NCT00640094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: melatonin
Description: Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
Study NCT03471455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
Study NCT03471455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
Study NCT03471455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
Study NCT01357213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 3AB
Description: Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
Study NCT01357213 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 100 ml
Study NCT02495337 — intervention group
Intervention type: OTHER
Intervention: Tissue Collection
Study NCT01009528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic feedback system on diabetes care
Description: An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
Study NCT01800188 — intervention group
Intervention type: PROCEDURE
Intervention: Hemodialysis
Description: A 4 hour hemodialysis with a standardized liquid meal after one hour
Study NCT01800188 — intervention group
Intervention type: PROCEDURE
Intervention: Hemodiafiltration
Description: A 4 hour hemodiafiltration with a standardized liquid meal after one hour
Study NCT01800188 — intervention group
Intervention type: PROCEDURE
Intervention: Meal test
Description: A 3 hour standardized liquid meal test without dialysis
Study NCT00437658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Provided as tablets for oral administration
Study NCT00437658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Description: Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.
Study NCT00437658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Elagolix
Description: Matching placebo tablets for oral administration
Study NCT00437658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to DMPA-SC
Description: Matching placebo for subcutaneous injection in a pre-filled syringe
Study NCT00379327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture administered in last three weeks of pregnancy
Study NCT02830516 — intervention group
Intervention type: OTHER
Intervention: Measurement of lung elastance by two methods
Description: Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
Study NCT00905346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 25 mg Capsules
Description: Topiramate Capsules 2 x 25 mg
Study NCT00905346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® 25 mg Capsules
Description: Topamax® Capsule 2 x 25 mg
Study NCT00905346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Applesauce
Description: Applesauce
Study NCT00905346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applesauce
Description: Applesauce
Study NCT00379327 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-puncturing Acupuncture Needle
Description: Streitsberg non-Acupuncture Needle
Study NCT01602653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK
Description: an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
Study NCT01602653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK
Description: an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
Study NCT04664621 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HepQuant
Description: Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.
Study NCT02325531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low support
Description: EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and~BASIC WEBINAR, Annual, 1-hour, topics such as:~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows
Study NCT02325531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medium support
Description: Same as provided to the low support arm, PLUS~* STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group~* ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 \& 3.
Study NCT02325531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High support
Description: Same as provided to the low and medium support arms, PLUS~- PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion.
Study NCT02325531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison
Description: No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR.
Study NCT00928525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
Study NCT06391606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: 2 pills/day of 150 mg CoQ10 phytosome (i.e. 300 mg CoQ10 phytosome per day)
Study NCT06391606 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 pills/day
Study NCT02372305 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FlexHD
Description: Patients will be randomized to receive FlexHD.
Study NCT02372305 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alloderm
Description: Patient will be randomized to receive Alloderm.
Study NCT02769715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-sintered removable partial denture
Description: The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).
Study NCT02769715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cast removable partial dentures
Description: The denture was fabricated traditionally using lost-wax casting technique.
Study NCT04212000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole tablet
Study NCT02305706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: starting position in colonoscopy
Study NCT02305706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: starting position in colonoscopy
Study NCT03884088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limits of Stability
Description: Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
Study NCT03884088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limits of Stability
Description: Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
Study NCT04212000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole tablet
Study NCT04271761 — intervention group
Intervention type: OTHER
Intervention: Non-interventional, post-market, pilot study of Carina Cochlear System
Description: Several objective acoustic measurements will be performed that do not require active participation from the subject.
Study NCT03170622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intervention group
Description: This group will provide a stool sample that will be analysed for VOCs and followed up after 3 months
Study NCT03365115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Intrathecal morphine 100 mcg will be injected.
Study NCT02357511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Monitor used
Study NCT01573312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASO3 Adjuvant
Description: 3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
Study NCT01573312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H5N1 Vaccine
Description: 3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
Study NCT03494556 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Paramedic will use data collected during routine care to complete four risk stratification tools.
Study NCT00883493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate XR
Description: Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
Study NCT00883493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Description: Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
Study NCT00756548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI850
Description: multi-dose preparation for oral administration prior to colonoscopy
Study NCT00756548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 3350 based bowel preparation
Description: multi-dose preparation for oral administration prior to colonoscopy
Study NCT03837184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Onasemnogene Abeparvovec-xioi
Description: Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
Study NCT02983604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5829
Description: Tablet(s) administered orally once daily
Study NCT03365115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Description: Intrathecal morphine 100 mcg will be injected.
Study NCT03365115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal fentanyl
Description: Intrathecal fentanyl 25 mcg will be injected.
Study NCT03365115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Description: Intrathecal fentanyl 25 mcg will be injected.
Study NCT00719745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study NCT00719745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR4
Description: oral
Study NCT03075553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03075553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT01209390 — intervention group
Intervention type: DEVICE
Intervention: Chondromimetic
Description: The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.~The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate.
Study NCT04694391 — intervention group
Intervention type: GENETIC
Intervention: whole exome sequence
Description: To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
Study NCT04472156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfer of mosaic embryo
Description: Subjects will transfer a mosaic embryo transferred to their uterus
Study NCT00818545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ER4017 (hydroxypropyltetrahydropyrantriol)
Description: Cream, 10%, each day during 3 months
Study NCT00591110 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye care education
Description: Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
Study NCT02983604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
Study NCT00591110 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Social-contact control
Description: Participants receive an engaging informational session on a non-health related topic
Study NCT03020446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorbion Dressing
Description: Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
Study NCT04357301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop vasopressor
Description: The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients
Study NCT00647829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
Study NCT00647829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
Study NCT00647829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet by mouth for 2 doses over a 24-hour period
Study NCT04204070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accuro
Description: A research coordinator recorded the depth of the EDS from skin, the number of attempts to perform the epidural anesthesia, the repositioning of the epidural needle either in the same space or in different space, the time taken for space localisation (it is defined as time taken in seconds from skin puncture until the successful space localisation).the total time of the procedure ( time measured from the patient is fully draped and in the proper sitting position till the end of insertion of the epidural catheter ) Any complications such as paresthesia during catheter insertion, dural puncture, blood in catheter and root irritation will be recorded
Study NCT02983604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15.
Study NCT02983604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15.
Study NCT02882256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Description: Discharge instructions provided in video form